Breaking News Instant updates and real-time market news.

OPHT

Ophthotech

$34.54

-4.42 (-11.35%)

, REGN

Regeneron

$390.38

-7.78 (-1.95%)

07:13
11/29/16
11/29
07:13
11/29/16
07:13

Ophthotech has no read through from competitor failure, says SunTrust

After Regeneron's (REGN) REGN2176-3 for wet AMD failed to show significant efficacy in a Phase II trial, SunTrust analyst Yatin Suneja does not believe that the failure bodes badly for Ophthotech (OPHT) whose Fovista treatment, like Regeneron's (REGN) drug, utilizes the PDGF pathway. The analyst says that Ophthotech's Fovista "has shown impressive efficacy in both Phase I and Phase IIb studies," and Suneja expects Fovista's Phase III results to also show strong efficacy. The analyst reiterates a $100 price target and a Buy rating on Ophthotech.

OPHT

Ophthotech

$34.54

-4.42 (-11.35%)

REGN

Regeneron

$390.38

-7.78 (-1.95%)

  • 03

    Dec

  • 29

    Mar

OPHT Ophthotech
$34.54

-4.42 (-11.35%)

09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/30/16
COWN
09/30/16
NO CHANGE
Target $60
COWN
Outperform
Ophthotech price target lowered to $60 from $80 at Cowen
Cowen analyst Tyler Van Buren said that Regeneron's (REGN) Phase 2 data for aflibercept co-formulated with rinucumab is negative for the class of anti-PDGFs as a whole and lowered his price target on Ophthotech (OPHT) to $60 from $80 after lowering his view of the probability of the success of its own wet AMD treatment to 50%. However, if a 3-4 letter benefit if observed when the Phase III trials read out in December, upside of $80-$120 per share from current levels is still possible, said Van Buren, who keeps an Outperform rating on Ophthotech shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
10/06/16
GSCO
10/06/16
NO CHANGE
Target $23
GSCO
Sell
Ophthotech price target lowered to $23 from $45 at Goldman
Goldman analyst Terence Flynn lowered Ophthotech's (OPHT) price target to $23 from $45 and reiterated his Sell rating. He revised is thesis on Ophthotech following Regeneron's (REGN) recent negative Phase II data for its co-formulation of Eylea with Rinucumab and is incrementally more cautious on success for Fovista currently in Phase III trials.
REGN Regeneron
$390.38

-7.78 (-1.95%)

11/07/16
CHDN
11/07/16
NO CHANGE
CHDN
Regeneron shyness on drug prices negative, says Chardan
Chardan analyst Gbola Amusa says that Regeneron's reluctance to comment on drug pricing pressures during its Q3 earnings call is very unusual for a large drug company. The analyst says that this development creates risk that "pricing dynamics for Regeneron are either unknown...or are perhaps so negative that consensus estimates would be downwardly revised if a robust discussion were to have occurred." The analyst believes that, for Regeneron's Eylea treatment to meet consensus estimates, data on three upcoming, competing products will have to be negative, and all pricing pressure on drugs would have to disappear. He keeps a Sell rating on the stock.
11/07/16
LEER
11/07/16
NO CHANGE
Target $504
LEER
Outperform
Regeneron price target lowered to $504 from $513 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Regeneron (REGN) to $504 from $513 on valuation. Porges expects near-term volatility for the stock given questions regarding the upcoming second interim analysis of the Odyssey Outcomes trial for Praluent, the restart of trials for pain treatment fasinumab after the FDA's clinical hold, and the issues regarding development partner Sanofi's (SNY) fill-finish plant leading to sarilumab's Complete Response Letter last week. He reiterates an Outperform on Regeneron's shares.
11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Piper sees Biotech rally continuing into 2017, lays out five to own
Piper Jaffray analyst Edward Tenthoff expects the rally in Biotechs, following "the trifecta" of a Trump Presidential election, Republican Congress sweep and defeat of Prop 61 in California, to continue into 2017. He recommends focusing on shares of Vertex (VRTX), Regeneron (REGN), Alnylam (ALNY), Exelixis (EXEL) and OncoMed (OMED). Tenthoff has a Neutral rating on Regeneron and Overweight ratings on the other four names.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.

TODAY'S FREE FLY STORIES

02:45
02/24/17
02/24
02:45
02/24/17
02:45
General news
FX Action: The dollar has been in consolidation »

FX Action: The dollar has…

HL

Hecla Mining

$6.07

-0.29 (-4.56%)

21:32
02/23/17
02/23
21:32
02/23/17
21:32
Upgrade
Hecla Mining rating change  »

Hecla Mining upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

RIG

Transocean

$14.31

1.03 (7.76%)

21:31
02/23/17
02/23
21:31
02/23/17
21:31
Downgrade
Transocean rating change  »

Transocean downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CYOU

Changyou.com

$27.47

-0.56 (-2.00%)

21:30
02/23/17
02/23
21:30
02/23/17
21:30
Upgrade
Changyou.com rating change  »

Changyou.com upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOUR

Tuniu

$8.51

-0.2 (-2.30%)

21:30
02/23/17
02/23
21:30
02/23/17
21:30
Upgrade
Tuniu rating change  »

Tuniu upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFUN

Fang Holdings

$3.00

-0.02 (-0.66%)

21:30
02/23/17
02/23
21:30
02/23/17
21:30
Downgrade
Fang Holdings rating change  »

Fang Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YY

YY

$45.72

-1.16 (-2.47%)

21:29
02/23/17
02/23
21:29
02/23/17
21:29
Downgrade
YY rating change  »

YY downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$27.56

-0.22 (-0.79%)

21:26
02/23/17
02/23
21:26
02/23/17
21:26
Downgrade
Sunoco rating change  »

Sunoco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

QUNR

Qunar

$30.39

-0.22 (-0.72%)

20:25
02/23/17
02/23
20:25
02/23/17
20:25
Conference/Events
Qunar to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

COG

Cabot Oil & Gas

$22.53

-0.07 (-0.31%)

, FL

Foot Locker

$68.58

-2.44 (-3.44%)

20:25
02/23/17
02/23
20:25
02/23/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

COG

Cabot Oil & Gas

$22.53

-0.07 (-0.31%)

FL

Foot Locker

$68.58

-2.44 (-3.44%)

JCP

J.C. Penney

$6.86

-0.19 (-2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

IIPR

Innovative Industrial Properties

$18.05

0.05 (0.28%)

20:04
02/23/17
02/23
20:04
02/23/17
20:04
Hot Stocks
White House: Likely to see 'greater enforcement' of federal marijuana laws »

During a press briefing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.53

-0.58 (-0.42%)

, SMCI

Super Micro Computer

$27.40

0.3 (1.11%)

19:55
02/23/17
02/23
19:55
02/23/17
19:55
Periodicals
Apple cut ties to Super Micro over security concerns, The Information says »

Apple (AAPL) terminated…

AAPL

Apple

$136.53

-0.58 (-0.42%)

SMCI

Super Micro Computer

$27.40

0.3 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 13

    Mar

HLF

Herbalife

$59.40

-1.34 (-2.21%)

19:45
02/23/17
02/23
19:45
02/23/17
19:45
Hot Stocks
Herbalife says board approves new $1.5B repurchase plan »

In its Q4 earnings report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

AHT

Ashford Hospitality

$7.37

-0.13 (-1.73%)

19:17
02/23/17
02/23
19:17
02/23/17
19:17
Earnings
Ashford Trust reports Q4 AFFO 16c, may not compare to consensus (32c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

PG

Procter & Gamble

$91.13

-0.31 (-0.34%)

, EPC

Edgewell Personal Care

$76.27

-5.44 (-6.66%)

19:13
02/23/17
02/23
19:13
02/23/17
19:13
Hot Stocks
Procter & Gamble says cutting Gillette prices by double digits »

Speaking during the…

PG

Procter & Gamble

$91.13

-0.31 (-0.34%)

EPC

Edgewell Personal Care

$76.27

-5.44 (-6.66%)

UL

Unilever; also tag UN

$46.90

-0.03 (-0.06%)

UN

Unilever; also tag UL

$46.58

-0.17 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 19

    Mar

NSU

Nevsun Resources

$2.94

-0.06 (-2.00%)

19:12
02/23/17
02/23
19:12
02/23/17
19:12
Hot Stocks
Nevsun Resources redeploys $120M to fund Timok »

Nevsun announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSU

Nevsun Resources

$2.94

-0.06 (-2.00%)

19:11
02/23/17
02/23
19:11
02/23/17
19:11
Hot Stocks
Nevsun plans to drill over 130,000 meters during 2017 across 3 countries »

The company is planning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSU

Nevsun Resources

$2.94

-0.06 (-2.00%)

19:10
02/23/17
02/23
19:10
02/23/17
19:10
Hot Stocks
Nevsun sees Bisha processing 2.4M tonnes of primary one in FY17 »

Nevsun expects Bisha to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSU

Nevsun Resources

$2.94

-0.06 (-2.00%)

19:10
02/23/17
02/23
19:10
02/23/17
19:10
Hot Stocks
Nevsun sees investing $45M at Timok Upper Zone Project in FY17 »

The company expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSU

Nevsun Resources

$2.94

-0.06 (-2.00%)

19:08
02/23/17
02/23
19:08
02/23/17
19:08
Earnings
Nevsun reports FY16 EPS 4c, consensus 7c »

Reports FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$76.88

-0.02 (-0.03%)

, S

Sprint

$8.96

-0.33 (-3.55%)

19:01
02/23/17
02/23
19:01
02/23/17
19:01
Hot Stocks
SoftBank, Sprint, TBCASoft partner in blockchain technology for telecoms »

SoftBank (SFTBF), Sprint…

SFTBF

SoftBank

$76.88

-0.02 (-0.03%)

S

Sprint

$8.96

-0.33 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

GOOG

Alphabet

$831.33

0.57 (0.07%)

, GOOGL

Alphabet Class A

$851.00

-0.36 (-0.04%)

18:59
02/23/17
02/23
18:59
02/23/17
18:59
Periodicals
Alphabet's Waymo sues Uber for allegedly stealing trade secrets, Bloomberg says »

Alphabet's Waymo…

GOOG

Alphabet

$831.33

0.57 (0.07%)

GOOGL

Alphabet Class A

$851.00

-0.36 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 06

    Mar

  • 19

    Mar

ALB

Albemarle

$92.41

-0.03 (-0.03%)

18:57
02/23/17
02/23
18:57
02/23/17
18:57
Hot Stocks
Albemarle raises quarterly dividend 5% to 32c from 30.5c per share »

The dividend, which has a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

UTX

United Technologies

$112.09

-0.57 (-0.51%)

18:32
02/23/17
02/23
18:32
02/23/17
18:32
Hot Stocks
Carrier expands air conditioner, heat pump recall »

United Technologies'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

BREW

Craft Brew

$15.60

-0.25 (-1.58%)

, BUD

AB InBev

$108.76

-0.4 (-0.37%)

18:17
02/23/17
02/23
18:17
02/23/17
18:17
Hot Stocks
Craft Brew reschedules Q4 report to allow additional time for audit »

Craft Brew Alliance…

BREW

Craft Brew

$15.60

-0.25 (-1.58%)

BUD

AB InBev

$108.76

-0.4 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.